Everolimus in pulmonary transplantation: Pharmacokinetics and exposure-response relationships

Journal of Heart and Lung Transplantation

Volumn 25, Issue 4, 2006, Pages 440-446

  Kovarik, John M ^a   Snell, Gregory I ^b   Valentine, Vincent ^c   Aris, Robert ^d   Chan, Charles K N ^e   Schmidli, Heinz ^a   Pirron, Ulrich ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ALFRED HOSPITAL   (Australia)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMIDAZOLE;

ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; LUNG FUNCTION; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AREA UNDER CURVE; AZATHIOPRINE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TREATMENT OUTCOME;

EID: 33645070240     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.12.001     Document Type: Article

References (13)

1. M.E. Bowdish, S.M. Arcasoy, J.S. Wilt Surrogate markers and risk factors for chronic lung allograft dysfunction Am J Transplant 4 2004 1171 1178
2. Certican (everolimus). Summary of product characteristics. Basel, Switzerland: Novartis Pharmaceuticals; 2004. Available from www.mpa.se/eng [accessed January 2006]
3. B. Nashan Review of the proliferation inhibitor everolimus Expert Opin Invest Drugs 11 2002 1845 1857
4. W. Schuler, R. Sedrani, S. Cottens SDZ RAD, a new rapamycin derivative pharmacological properties in vitro and in vivo Transplantation 64 1997 36 42
5. A. Azzola, A. Havryk, P. Chhajed Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation Transplantation 77 2004 275 280
6. G.I. Snell, V.G. Valentine, P. Vitulo Everolimus versus azathioprine in maintenance lung transplant recipients an international, randomized, double-blind clinical trial Am J Transplant 6 2006 169 177
7. N. Brignol, L. McMahon, S. Luo, F.L.S. Tse High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometry analysis of everolimus (RAD001) and cyclosporine A (CsA) in whole blood Rapid Commun Mass Spectrom 15 2001 898 907
8. T.C. Chou, P. Talalay Quantitative analysis of dose-effect relationships the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
9. J.M. Kovarik, C.H. Hsu, L. McMahon, S. Berthier, C. Rordorf Population pharmacokinetics of everolimus in de novo renal transplant patients impact of ethnicity and comedications Clin Pharmacol Ther 70 2001 247 254
10. R.L. Doyle, M.I. Hertz, J.M. Dunitz RAD in stable lung and heart/lung transplant recipients safety, tolerability, pharmacokinetics, and impact of cystic fibrosis J Heart Lung Transplant 20 2001 330 339
11. J.M. Kovarik, D. Beyer, M.N. Bizot Blood concentrations of everolimus are markedly increased by ketoconazole J Clin Pharmacol 45 2005 514 518
12. B.D. Kahan, R.L. Wong, C. Carter A phase 1 study of a 4-week course of SDZ-RAD in quiescent cyclosporine-prednisone-treated renal transplant patients Transplantation 68 1999 1100 1106
13. S. Vitko, R. Margreiter, W. Weimar Everolimus 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients Transplantation 78 2004 1532 1540